September 25, 2021
Article
With the Oncology Care Model (OCM) slated to end in 2022, the successor model is still not in place. According to panelists, there is likely going to be a gap after OCM ends and the new model begins, but more importantly, practices should prepare for the new model to be mandatory.
September 09, 2021
The administration said it would make the results of its drug price negotiations with manufacturers, as well as its approach to value-based care models, open to a variety of payers.
August 10, 2021
Webinar
In segment 5, the panelists discuss the impact of COVID-19 and future considerations for clinical research.
In segment 4, the panelists discuss regulatory considerations for real-world evidence and real-world data.
In segment 3, the panelists discuss the impacts of real-world evidence and real-world data on drug evaluation.
In segment 2, the panelists discuss FDA's efforts to modernize drug evaluation.
In the latest Oncology Value Coalition from The American Journal of Managed Care®, Bruce Feinberg, DO, led a discussion on how the traditional one-size-fits-all clinical development and regulatory approval paradigm has evolved to become an increasingly customizable process.
July 27, 2021
In the June Matters in Managed Care webinar, experts from Blue Cross and Blue Shield of North Carolina, Duke-Margolis Center for Health Policy, UNC Center for the Business of Health, and WakeMed discussed how they are working together to address some of the state’s unique primary care needs.
